T1	Participants 572 688	Eight hundred and ninety-one patients treated for 48 weeks with an initial ribavirin dose of 800 or 1000/1200 mg/day
T2	Participants 462 562	treatment-naive patients with HCV genotype 1 infection enrolled in a large expanded access programme
